Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Judy Dering"'
Autor:
Michael F. Press, Catherine E. Ellis, L. O'Rourke, Anne-Marie Martin, Richard S. Finn, Judy Dering, Stephen R. D. Johnston, A. Florance
Publikováno v:
Clinical Cancer Research. 20:736-743
Purpose: Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 inhibitor, remains unproven in non–HER2-amplified metastatic breast cancer (MBC). EGF30008, a phase III trial of letrozole and lapatinib versus letrozole and placebo, demon
Autor:
Diana C. Márquez-Garbán, Sharon Pitts, Amrita J. Desai, Richard J. Pietras, Wylie Hosmer, Richard S. Finn, Dennis J. Slamon, Erika von Euw, Judy Dering, Steven M. Dubinett, Naeimeh Kamranpour, Edward B. Garon
Publikováno v:
Journal of Thoracic Oncology. 8(3):270-278
Introduction Estrogen receptor (ER) signaling and its interaction with epidermal growth factor receptor (EGFR) is a potential therapeutic target in non–small-cell lung cancer (NSCLC). To explore cross-communication between ER and EGFR, we have corr
Autor:
Manway Liu, Wylie Hosmer, Michael Rugaard Jensen, Judy Dering, Richard S. Finn, Emin Avsar, Dennis J. Slamon, Habib Hamidi, Sharon Pitts, Steven M. Dubinett, Amrita J. Desai, Susan Ide, Edward B. Garon, Cornelia Quadt, Naeimeh Kamranpour
Publikováno v:
Molecular cancer therapeutics. 12(6)
Heat shock protein 90 (HSP90) is involved in protein folding and functions as a chaperone for numerous client proteins, many of which are important in non–small cell lung cancer (NSCLC) pathogenesis. We sought to define preclinical effects of the H
Autor:
Richard S. Finn, M. Arbushites, Judy Dering, Angelo Di Leo, Michael F. Press, Cristina Oliva, Maria Koehler, L. S. Williams
Purpose Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with activity in HER2-amplified metastatic breast cancer (MBC). Its role in non–HER2-amplified MBC remains unclear.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c584487992e4d4d01014e19bc8613da4
https://europepmc.org/articles/PMC2799151/
https://europepmc.org/articles/PMC2799151/
Autor:
S. Stein, Michael F. Press, Angelo Di Leo, M. Arbushites, Zanete Zvirbule, Stephanie F. Guerrera, Zeba Aziz, Richard S. Finn, L. S. Williams, Judy Dering, Cristina Oliva, Maria Koehler, José Bines, Henry L. Gomez
Purpose Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective against HER-2–positive locally advanced or metastatic breast cancer (MBC).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f4fb91c82d9a0d5dcb4fd11bf1c5de7
https://europepmc.org/articles/PMC2651098/
https://europepmc.org/articles/PMC2651098/
Autor:
Karl C. Podratz, D Toft, Richard S. Finn, Gottfried E. Konecny, C Ginther, M Schoenberg Fejzo, Judy Dering, Natarajan Venkatesan, M Rahmeh, Dennis J. Slamon, S-W Jiang, Guorong Yang
Publikováno v:
British Journal of Cancer
In this study, we explore the therapeutic potential of lapatinib a selective inhibitor of both the EGFR and HER2 tyrosine kinases for the treatment of endometrial cancer. The effect of lapatinib on tumour cell growth and receptor activation was studi